THE C12-200 DIARIES

Avelumab received orphan drug standing and breakthrough therapy designation for this indication, and the appliance was granted precedence critique. Being a problem of accelerated acceptance, an added analyze is needed to substantiate the clinical advantage of avelumab for this indicator.Posterior reversible encephalopathy syndrome (PRES) has been